Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Maddocks K, Pagel JM, O'Brien S, et al.
Key Points:
Otlertuzumab, a CD37-specific monoclonal antibody, demonstrated promising anti-tumor activity in preclinical models
In this phase 1b trial, otlertuzumab in combination with rituximab in previously untreated CLL patients showed that combination was safe and well-tolerable
Most serious adverse events included neutropenia, pneumonia, systemic inflammatory response, and deep vein thrombosis
Preliminary analysis of clinical efficacy data indicated an ORR of 88%
Implications:
- Preliminary clinical safety and efficacy data of otlertuzumab in combination with rituximab in treatment naive patients with CLL is promising
View the original abstract on the ASH website.
